Abstract:Significance: Protein neddylation is catalyzed by an E1 NEDD8-activating enzyme (NAE), an E2 NEDD8-conjugating enzyme, and an E3 NEDD8 ligase. Known physiological substrates of neddylation are cullin family members. Cullin neddylation leads to activation of cullin-RING ligases (CRLs), the largest family of E3 ubiquitin ligases responsible for ubiquitylation and degradation of many key signaling/regulatory proteins. Thus, through modulating CRLs, neddylation regulates many biological processes, including cell cycle progression, signal transduction, and tumorigenesis. Given that NEDD8 is overexpressed and CRLs are abnormally activated in many human cancers, targeting protein neddylation, in general, and cullin neddylation, in particular, appears to be an attractive anticancer approach. Recent Advances: MLN4924, a small molecule inhibitor of NAE, was discovered that inactivates CRLs and causes accumulation of CRL substrates to suppress tumor cell growth both in vitro and in vivo. Promising preclinical results advanced MLN4924 to several clinical trials for anticancer therapy. Critical Issues: In preclinical settings, MLN4924 effectively suppresses tumor cell growth by inducing apoptosis, senescence, and autophagy, and causes sensitization to chemoradiation therapies in a cellular context-dependent manner. Signal molecules that determine the cell fate upon MLN4924 treatment, however, remain elusive. Cancer cells develop MLN4924 resistance by selecting target mutations. Future Directions: In the clinical side, several Phase 1b trials are under way to determine the safety and efficacy of MLN4924, acting alone or in combination with conventional chemotherapy, against human solid tumors. In the preclinical side, the efforts are being made to develop additional neddylation inhibitors by targeting NEDD8 E2s and E3s. Antioxid. Redox Signal. 21, 2383-2400.

Progress in the researches for antitumor NEDD8 activating enzyme inhibitors

Targeting NEDD8-activating enzyme for cancer therapy: developments, clinical trials, challenges and future research directions

Neddylation promotes protein translocation between the cytoplasm and nucleus

Discovery of small molecule inhibitors of neddylation catalyzing enzymes for anticancer therapy

Protein Neddylation and Its Alterations in Human Cancers for Targeted Therapy.

Development of Potent NEDD8-Activating Enzyme Inhibitors Bearing a Pyrimidotriazole Scaffold.

Targeting Neddylation Pathways to Inactivate Cullin-RING Ligases for Anticancer Therapy

Identification of novel benzoyl hydrazine derivatives as activators of neddylation pathway to inhibit the tumor progression in vitro

Progress in Function and Regulation of Protein Neddylation

Research progress in neddylation and its function in cells

Anticancer Drug Discovery by Targeting Cullin Neddylation

Review of NEDDylation inhibition activity detection methods

NEDD8-conjugating Enzyme E2s: Critical Targets for Cancer Therapy

Protein neddylation and its role in health and diseases

Targeting DCN1-UBC12 Protein-Protein Interaction for Regulation of Neddylation Pathway

The many substrates and functions of NEDD4-1

Discovery of novel tertiary amide derivatives as NEDDylation pathway activators to inhibit the tumor progression <i>in vitro</i> and <i>in vivo</i>

Advancements in colorectal cancer research: Unveiling the cellular and molecular mechanisms of neddylation (Review)

Advances of relationship between protein Neddylation and cancer

Suppression of tumor angiogenesis by targeting the protein neddylation pathway.

NAE modulators: A potential therapy for gastric carcinoma